MDB Capital Reports Q3 2026 Results Highlighting Reduced Cash Burn and Subsidiary Strategic Focus
MDB Capital (MDBH) has transitioned to a leaner operational model, focusing on reducing parent-level cash burn by seeking external financing and partnerships for its four core subsidiaries: Public Ventures, PatentVest, eXoZymes, and Paulex Bio. The company reported $4.2 million in fee income for the first nine months of the period and maintains an operating cash position of $8.3 million. Management is working toward a 2027 target to distribute subsidiary assets to shareholders as they reach commercial inflection points. While eXoZymes has significantly reduced manufacturing costs for its products, Paulex Bio faces a slight delay in clinical trials, with first patient dosing now expected in December 2026 rather than September.

Topics: cash burn clinical trials earnings call operating expenses subsidiary performance